Literature DB >> 25243626

Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure.

A Ghobadi1, E Nolley2, J Liu3, A McBride1, K Stockerl-Goldstein1, A Cashen1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25243626      PMCID： PMC4908813          DOI： 10.1038/bmt.2014.198

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.

Authors:  Ivan Aksentijevich; Richard J Jones; Richard F Ambinder; Elizabeth Garrett-Mayer; Ian W Flinn
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

3.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

5.  Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

Authors:  Richard T Doocey; Cynthia L Toze; Joseph M Connors; Thomas J Nevill; Randy D Gascoyne; Michael J Barnett; Donna L Forrest; Donna E Hogge; Julye C Lavoie; Stephen H Nantel; John D Shepherd; Heather J Sutherland; Nicholas J Voss; Clayton A Smith; Kevin W Song
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

6.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

7.  A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Authors:  Hillard M Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M Hayes-Lattin; Asli Selmin Ataergin; Jacob D Bitran; Brian J Bolwell; César O Freytes; Robert Peter Gale; Steven C Goldstein; Gregory A Hale; David J Inwards; Thomas R Klumpp; David I Marks; Richard T Maziarz; Philip L McCarthy; Santiago Pavlovsky; J Douglas Rizzo; Thomas C Shea; Harry C Schouten; Shimon Slavin; Jane N Winter; Koen van Besien; Julie M Vose; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-04       Impact factor: 5.742

8.  Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

Authors:  Julie M Vose; Douglas J Rizzo; Jing Tao-Wu; James O Armitage; Asad Bashey; Linda J Burns; Neal Paul Christiansen; Cesar O Freytes; Robert Peter Gale; John Gibson; Sergio A Giralt; Roger H Herzig; Charles F Lemaistre; Philip L McCarthy; Stephen D Nimer; Finn B Petersen; David P Schenkein; Peter H Wiernik; Joseph M Wiley; Fausto R Loberiza; Hillard M Lazarus; Koen van Biesen; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2004-02       Impact factor: 5.742

9.  Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.

Authors:  L J Costa; I N Micallef; D J Inwards; P B Johnston; L F Porrata; S M Ansell
Journal:  Bone Marrow Transplant       Date:  2008-01-14       Impact factor: 5.483

10.  Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.

Authors:  C Guglielmi; F Gomez; T Philip; A Hagenbeek; M Martelli; C Sebban; N Milpied; D Bron; J Y Cahn; R Somers; P Sonneveld; C Gisselbrecht; H Van Der Lelie; F Chauvin
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544
  10 in total
  2 in total

Review 1.  Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Authors:  Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

2.  Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma.

Authors:  Karlo Perica; Lia Palomba; Renier J Brentjens
Journal:  Adv Cell Gene Ther       Date:  2018-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.